{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T21:07:04Z","timestamp":1776892024552,"version":"3.51.2"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.intimp.2026.116301","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:42:06Z","timestamp":1769917326000},"page":"116301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mechanism of vildagliptin-induced liver injury: An idiosyncratic drug reaction mediated by inflammasome activation"],"prefix":"10.1016","volume":"173","author":[{"given":"Serina","family":"Mizuguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Urashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Tamura-Takaori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Kidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jina","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Kohda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116301_bb0005","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/HEP.0000000000000341","article-title":"Spatial metabolomics and its application in the liver","volume":"79","author":"Santos","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2026.116301_bb0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-024-02072-z","article-title":"Liver diseases: epidemiology, causes, trends and predictions","volume":"10","author":"Gan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116301_bb0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.intimp.2026.116301_bib303","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.23","article-title":"Drug-induced liver injury: the role of drug metabolism and transport","volume":"53","author":"Corsini","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116301_bb0020","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.3390\/ijms23116049","article-title":"Challenges and future of drug-induced liver injury research\u2014laboratory tests","volume":"23","author":"Weber","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116301_bb0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.5858\/arpa.2014-0214-RA","article-title":"Drug-induced liver injury","volume":"139","author":"Fisher","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.intimp.2026.116301_bb0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/toxsci\/kfae054","article-title":"The role of corticosterone in nevirapine-induced idiosyncratic drug-induced liver injury","volume":"200","author":"Jee","year":"2024","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.intimp.2026.116301_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2023.105606","article-title":"Mechanism of non-steroidal anti-androgen-induced liver injury: reactive metabolites of flutamide and bicalutamide activate inflammasomes","volume":"90","author":"Kato","year":"2023","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.intimp.2026.116301_bb0040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/toxsci\/kfx219","article-title":"Editor's highlight: an impaired immune tolerance animal model distinguishes the potential of troglitazone\/pioglitazone and tolcapone\/entacapone to cause IDILI","volume":"161","author":"Mak","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.intimp.2026.116301_bb0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.20567","article-title":"Troglitazone and liver injury: in search of answers","volume":"41","author":"Chojkier","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2026.116301_bb0050","article-title":"11th edition of the IDF diabetes atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","author":"Genitsaridi","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.intimp.2026.116301_bb0055","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","article-title":"Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)","volume":"23","author":"Thornberry","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2026.116301_bb0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/jdi.13945","article-title":"Updates of incretin-related drugs for the treatment of type2 diabetes","volume":"14","author":"Araki","year":"2023","journal-title":"J. Diabetes Invest."},{"key":"10.1016\/j.intimp.2026.116301_bb0065","series-title":"Galvus 50 mg tablets\u2013Summary of Product Characteristics (SmPC) Available at: www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000771\/WC500020327.pdf (accessed 18 September 2025)","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.intimp.2026.116301_bb0070","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.2337\/dc14-1252","article-title":"Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a Hemodialyzed diabetic patient","volume":"37","author":"Kurita","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.intimp.2026.116301_bb0075","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.bmcl.2006.11.044","article-title":"A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds","volume":"17","author":"Oballa","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2026.116301_bb0080","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bcp.2018.08.043","article-title":"Identification of a novel metabolite of vildagliptin in humans: cysteine targets the nitrile moiety to form a thiazoline ring","volume":"156","author":"Mizuno","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116301_bb0085","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/jat.4751","article-title":"Reactive metabolites cause idiosyncratic drug-induced liver injury via inflammasome activation in antigen-presenting cells","volume":"45","author":"Kato","year":"2025","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.intimp.2026.116301_bb0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00018-025-05744-3","article-title":"Mechanisms of drug induced liver injury","volume":"82","author":"Skat-R\u00f8rdam","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2026.116301_bb0095","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.18295\/2075-0528.1648","article-title":"The role of damage-associated molecular patterns in human diseases: part I - promoting inflammation and immunity","volume":"15","author":"Land","year":"2015","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"10.1016\/j.intimp.2026.116301_bib304","first-page":"145","article-title":"Immune mechanisms of idiosyncratic drug-induced liver injury","volume":"3","author":"Mak","year":"2017","journal-title":"J. Clin. Transl. Res."},{"key":"10.1016\/j.intimp.2026.116301_bb0100","first-page":"7","article-title":"Heat shock proteins in protein folding and reactivation","volume":"29","author":"Malkeyeva","year":"2025","journal-title":"Vavilovskii Zhurnal Genet Selektsii."},{"key":"10.1016\/j.intimp.2026.116301_bb0105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/978-3-642-00663-0_18","article-title":"The danger hypothesis applied to idiosyncratic drug reactions","author":"Li","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116301_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184508","article-title":"Heat shock proteins and inflammasomes","volume":"20","author":"Martine","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116301_bb0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/liv.12988","article-title":"Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications","volume":"36","author":"Dara","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.intimp.2026.116301_bb0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116301_bb0125","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/acs.chemrestox.5b00305","article-title":"The combination of anti-CTLA-4 and PD1\u2212\/\u2212 mice unmasks the potential of isoniazid and nevirapine to cause liver injury","volume":"28","author":"Mak","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.intimp.2026.116301_bb0130","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/acs.chemrestox.0c00485","article-title":"Liver injury caused by green tea extract in PD-1(\u2212\/\u2212) mice: an impaired immune tolerance model for idiosyncratic drug-induced liver injury","volume":"34","author":"Cho","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.intimp.2026.116301_bb0135","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1002\/jcp.23033","article-title":"A novel human hepatoma cell line, FLC-4, exhibits highly enhanced liver differentiation functions through the three-dimensional cell shape","volume":"227","author":"Laurent","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.intimp.2026.116301_bb0140","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1242\/bio.20121438","article-title":"Spherical cell shape of FLC-4 cell, a human hepatoma cell, enhances hepatocyte-specific function and suppresses tumor phenotype through the integration of mRNA-microRNA interaction","volume":"1","author":"Laurent","year":"2012","journal-title":"Biol. Open"},{"key":"10.1016\/j.intimp.2026.116301_bb0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clinthera.2008.03.004","article-title":"Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes","volume":"30","author":"Covington","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2026.116301_bb0150","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.clinthera.2010.06.004","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects","volume":"32","author":"Sarashina","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2026.116301_bb0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2006.01.015","article-title":"Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers","volume":"28","author":"Bergman","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2026.116301_bb0160","doi-asserted-by":"crossref","first-page":"582","DOI":"10.5414\/CPP48582","article-title":"Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes","volume":"48","author":"He","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.116301_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2025.117310","article-title":"Brigatinib activates inflammasomes: implication for immune-related adverse events","volume":"498","author":"Noda","year":"2025","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116301_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100509","article-title":"Development of a fluorescent-labeled trapping reagent to evaluate the risk posed by acyl-CoA conjugates","volume":"52","author":"Shibazaki","year":"2023","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.intimp.2026.116301_bb0175","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/17425255.2022.2113379","article-title":"Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury","volume":"18","author":"Roth","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.intimp.2026.116301_bb0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/liv.13931","article-title":"The diagnosis and management of idiosyncratic drug-induced liver injury","volume":"39","author":"Hassan","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.intimp.2026.116301_bb0185","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3389\/fphar.2019.01235","article-title":"Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin-dependent kinase 4\/6 inhibitors","volume":"10","author":"Raschi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116301_bb0190","article-title":"NLRP3 inflammasome: checkpoint connecting innate and adaptive immunity in autoimmune diseases","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116301_bb0195","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.3390\/molecules23112846","article-title":"Heat shock proteins as Immunomodulants","volume":"23","author":"Zininga","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2026.116301_bb0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/nu12030611","article-title":"Glycine attenuates lipopolysaccharide-induced acute lung injury by regulating NLRP3 inflammasome and NRF2 Signaling","volume":"12","author":"Zhang","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2026.116301_bb0205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00002018-199921050-00005","article-title":"Comparative tolerability of the newer fluoroquinolone antibacterials","volume":"21","author":"Ball","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.intimp.2026.116301_bb0210","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/jat.4585","article-title":"Reactive metabolite of trovafloxacin activates inflammasomes: implications for trovafloxacin-induced liver injury","volume":"44","author":"Tanaka","year":"2024","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.intimp.2026.116301_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1663547","article-title":"S100 proteins as a key immunoregulatory mechanism for NLRP3 inflammasome","volume":"16","author":"Acter","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116301_bb0220","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/antiox10030390","article-title":"Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice","volume":"10","author":"Villanueva-Paz","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.intimp.2026.116301_bb0225","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","article-title":"Release mechanisms of major DAMPs","volume":"26","author":"Murao","year":"2021","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2026.116301_bb0230","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbrc.2013.03.010","article-title":"A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site","volume":"434","author":"Nabeno","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2026.116301_bb0235","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/jat.4332","article-title":"Reactive oxygen species-mediated activation of NLRP3 inflammasome associated with pyroptosis in Het-1A cells induced by the co-exposure of nitrosamines","volume":"42","author":"Liu","year":"2022","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.intimp.2026.116301_bb0240","doi-asserted-by":"crossref","first-page":"41","DOI":"10.22456\/2527-2616.133259","article-title":"Sitagliptin phosphate: isolation and identification of two degradation products formed under acid conditions and determination of in vitro cytotoxicity","volume":"7","author":"Lange","year":"2023","journal-title":"Drug Analytical Research"},{"key":"10.1016\/j.intimp.2026.116301_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115861","article-title":"Comprehensive UHPLC-MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation","volume":"238","author":"Jire\u0161","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.intimp.2026.116301_bb0250","article-title":"Nitrosation of piperazine in man","volume":"171-178","author":"Bellander","year":"1984","journal-title":"IARC Sci. Publ."},{"key":"10.1016\/j.intimp.2026.116301_bb0255","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1039\/D4CC05423G","article-title":"Nanosensor quantitative monitoring of ROS\/RNS homeostasis in single phagolysosomes of macrophages during bactericidal processes","volume":"61","author":"Guo","year":"2024","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.intimp.2026.116301_bb0260","series-title":"In vitro prediction of organ toxicity: the challenges of scaling and secondary mechanisms of toxicity","first-page":"353","author":"Hengstler","year":"2025"},{"key":"10.1016\/j.intimp.2026.116301_bb0265","article-title":"Hepatotoxicity of antimycotics used for invasive fungal infections","volume":"2017","author":"Do\u00df","year":"2017","journal-title":"In Vitro Results, Biomed Res Int."},{"key":"10.1016\/j.intimp.2026.116301_bb0270","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1002\/bit.27931","article-title":"An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury","volume":"118","author":"Xiao","year":"2021","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.intimp.2026.116301_bb0275","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep.27549","article-title":"Treatment of PD-1(\u2212\/\u2212) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients","volume":"61","author":"Metushi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2026.116301_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116301_bb0285","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000392","article-title":"Granulomatous liver diseases","volume":"8","author":"Mironova","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.intimp.2026.116301_bb0290","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/00185787231151861","article-title":"Bullous pemphigoid associated with dipeptidyl Peptidase-4 inhibitors: a case report and review of current evidence","volume":"58","author":"Hadjkacem","year":"2023","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.intimp.2026.116301_bb0295","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.4049\/jimmunol.1103801","article-title":"Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26)","volume":"188","author":"Bengsch","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116301_bb0300","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3390\/diagnostics14171958","article-title":"A case of bullous pemphigoid with significant infiltration of CD4-positive T cells during treatment with pembrolizumab, accompanied by pembrolizumab-induced multi-organ dysfunction","volume":"14","author":"Mima","year":"2024","journal-title":"Diagnostics"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:12:19Z","timestamp":1776769939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692600144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":62,"alternative-id":["S156757692600144X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116301","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism of vildagliptin-induced liver injury: An idiosyncratic drug reaction mediated by inflammasome activation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116301"}}